Copyright
©The Author(s) 2022.
World J Clin Oncol. Dec 24, 2022; 13(12): 943-956
Published online Dec 24, 2022. doi: 10.5306/wjco.v13.i12.943
Published online Dec 24, 2022. doi: 10.5306/wjco.v13.i12.943
Ref. | Year | n | Perforation rate (%) | Stoma rate (%) | Morbidity (%) | Mortality (%) |
Cheung et al[46] | 2009 | 48 | 0 | SEMS, 0; ES, 25, (P = 0.03)a | SEMS, 8; ES, 70; (P = N/A) | N/A |
Van Hooft et al[51] | 2011 | 98 | 12 | SEMS, 57; ES, 66; (P = 0.35) | SEMS, 53; ES, 45; (P = 0.43) | SEMS, 19; ES, 17; (P = 0.84) |
Pirlet et al[52] | 2011 | 60 | 6.6 | SEMS, 43; ES, 56; (P = 0.3) | SEMS, 50; ES, 56; (P = 1) | SEMS, 10; ES, 3; (P = N/A) |
Alcántara et al[47] | 2011 | 28 | 0 | N/A | SEMS, 13; ES, 54; (P = 0.042)a | SEMS, 0; ES, 8; (P = 0.46) |
Ho et al[50] | 2012 | 39 | 0 | SEMS, 10; ES, 31; (P = 0.12) | SEMS, 35; ES, 58; (P = 0.15) | SEMS, 0; ES, 16; (P = 0.1) |
Ghazal et al[48] | 2013 | 60 | 0 | N/A | SEMS, 13; ES, 50; (P = 0.012)a | SEMS, 0; ES, 0 |
Arezzo et al[15] | 2017 | 115 | 8.9 | SEMS, 22; ES, 39; (P = 0.031)a | SEMS, 52; ES, 58; (P = 0.529) | SEMS, 7; ES, 5; (P = 0.943) |
Elwan et al[49] | 2020 | 601 | 0 | SEMS, 20; ES, 27; (P = N/A) | SEMS, 23; ES, 40; (P = 0.029)a | N/A |
CReST trial[53] | 2022 | 2172 | 3.33 | SEMS, 43; ES, 67; (P < 0.001)a | SEMS, 34; ES, 35; (P = 0.930) | SEMS, 4; ES, 6; (P = 0.480) |
Ref. | Year | n | Perforation rate (%) | Median F/U time (mo) | Recurrence (%) | Overall survival (OS, %) | Disease-free survival (DFS, %) |
Alcántara et al[47] | 2011 | 28 | 0 | 38 | SEMS, 53; ES, 15; (P = 0.055) | 5-yr OS: SEMS, 60; ES, 68; (P = 0.843) | Disease-free period (mo): SEMS, 25; ES, 27; (P = 0.096) |
Tung et al[74] | 2013 | 48 | 0 | 32 | SEMS, 46; ES, 13; (P = 0.400) | 5-yr OS: SEMS, 48; ES, 27; (P = 0.076) | 5-yr DFS: SEMS, 52; ES, 48; (P = 0.630) |
Ghazal et al[48] | 2013 | 60 | 0 | 18 | SEMS, 17; ES, 13; (P = 0.228) | N/A | N/A |
Sloothaak et al[57] | 2014 | 58 | 23 | 43 | SEMS, 50; ES, 28; (P = N/A) | 4-yr OS: SEMS, 58; ES, 67; (P = 0.478) | 4-yr DFS: SEMS, 30; ES, 49; (P=0.007)a |
Arezzo et al[75] | 2020 | 115 | 8.9 | 37 | SEMS, 28; ES, 36; (P = N/A) | 3-yr OS: SEMS, 63; ES, 68; (P = 0.822) | 3-yr DFS: SEMS, 50; ES, 56; (P = 0.972) |
CReST trial[53] | 2022 | 2171 | 3.32 | N/A | 3-yr recurrence: SEMS, 43; ES, 34; (P = 0.340) | 3-yr OS: SEMS, 46; ES, 37; (P = 0.560) | N/A |
- Citation: Pattarajierapan S, Sukphol N, Junmitsakul K, Khomvilai S. Oncologic safety of colonic stenting as a bridge to surgery in left-sided malignant colonic obstruction: Current evidence and prospects. World J Clin Oncol 2022; 13(12): 943-956
- URL: https://www.wjgnet.com/2218-4333/full/v13/i12/943.htm
- DOI: https://dx.doi.org/10.5306/wjco.v13.i12.943